News for Merit Medical Systems, Inc. (MMSI)

In a recent update, Needham's analyst Mike Matson has announced a revised price target for Merit Medical Systems (MMSI), increasing it from USD 100.00 to USD 10

The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target l

Merit Medical Systems has secured regulatory approval from Health Canada for its Wrapsody Cell-Impermeable Endoprosthesis. This approval paves the way for the c

Merit Medical (NASDAQ: MMSI) receives Health Canada approval for WRAPSODY Cell-Impermeable Endoprosthesis. WRAPSODY CIE demonstrates superior clinical o

In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 m

Merit Medical Systems (MMSI) shared encouraging 12-month outcomes from the single-arm cohort of the WAVE trial during the Charing Cross Symposium in London, on

\n Merit Medical Systems (MMSI) reports 81.4% target lesion primary patency (TLPP) at 6 months, exceeding performance goals by 21.4 percentage points. The

Merit Medical Systems Inc. (MMSI) has experienced a reduction in its price target from Barrington Research analyst Michael Petusky. Previously set at $111, the

Raymond James has revised its outlook on Merit Medical Systems (MMSI), reducing the stock's price target from $116 to $108. Despite this adjustment, the firm ma

Baird analyst David Rescott has revised the price target for Merit Medical Systems, Inc. (MMSI), now setting it at $110, slightly down from the previous $111. D

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. ( MMSI), a global leader of healthcare technology, announced that Chairman

On March 3, 2025, Stephen Evans, a Director at Merit Medical Systems Inc (MMSI), sold 5,000 shares of the company, according to a SEC Filing. Following this tra

Merit Medical Systems Inc's robust product portfolio and market presence underscore its competitive strengths.Recent strategic acquisitions have expanded the c

Total Revenue: $355.2 million, up 9% year-over-year on a GAAP basis and 10% on a constant currency basis.Non-GAAP Operating Margin: 19.6% of sales, up approxim

Merit Medical Systems, Inc. (NASDAQ:MMSI) Q4 2024 Results Conference Call February 25, 2025 5:00 PM ETCompany ParticipantsFred Lampropoulos - Founder,...

Fourth Quarter Highlights”  Reported revenue of $355.2 million, up 9.4%Constant currency revenue* and constant currency revenue, organic* up 10.1% and u

Fresenius Medical, Masimo, Merit Medical Systems and Inogen are included in this Analyst Blog.

Merit Medical Systems Inc (MMSI) is set to release its Q4 2024 earnings on Feb 25, 2025. The consensus estimate for Q4 2024 revenue is $351.35 million, and the